Bull vs Bear: Dr Lal Path Labs a Tug-of-War with facts between Bulls and Bears

Bullish Arguments: Over 12% jump in non-covid portfolio. Acquisition will reduce the cost of testing, and reach will also increase. Income growth is possible by starting many other tests. City Buying Opinion, Target ₹ 3460. Bearish Arguments: Worse than expected results, margins fall by more than 3%. Changes in B2C Lab Testing prices may affect profits. The reduction in covid testing will have an impact on the total volume. CLSA sell sentiment remains intact, target ₹ 2100.